So it’s official. After an article in the New York Times this morning reported that GlaxoSmithKline (GSK) is near a deal to buy Human Genome Sciences (HGS) on friendly terms, HGS and GSK issued a press release making it official.
So the question our local biotech community is probably asking is: What’s next? What does/will this acquisition mean for Montgomery County’s biotech community? We certainly don’t want to see HGS — or any portion of it — relocated out of the area. Is that on the table? We don’t know.
What do you think? Will this buyout be good for the local biotech community? Or somehow hurt it? And what does this mean for HGS President & CEO H. Thomas Watkins, who is one of the “who’s who” of the local biotech community? There’s nothing in the press release about what his role will be after the acquisition.
We want to hear your thoughts. Go to our LinkedIn group to comment.